BRAINSWAY LTD/S (NASDAQ:BWAY) Upgraded by Zacks Investment Research to “Hold”

BRAINSWAY LTD/S (NASDAQ:BWAY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday, reports.

According to Zacks, “BrainsWay Ltd. is a commercial stage medical device company. It is focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation technology for the treatment of major depressive disorder and obsessive-compulsive disorder. BrainsWay Ltd. is based in Jerusalem, Israel. “

BWAY opened at $8.53 on Monday. The business has a 50 day moving average of $9.65. BRAINSWAY LTD/S has a 1 year low of $8.00 and a 1 year high of $12.39.

BRAINSWAY LTD/S (NASDAQ:BWAY) last announced its quarterly earnings results on Monday, August 26th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). The business had revenue of $5.70 million for the quarter, compared to analysts’ expectations of $5.30 million. Analysts anticipate that BRAINSWAY LTD/S will post -0.52 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in BWAY. Victory Capital Management Inc. acquired a new position in BRAINSWAY LTD/S during the second quarter valued at approximately $157,000. Noked Capital LTD acquired a new position in shares of BRAINSWAY LTD/S during the second quarter worth $572,000. ARK Investment Management LLC acquired a new position in shares of BRAINSWAY LTD/S during the second quarter worth $863,000. Finally, Delek Group Ltd. acquired a new position in shares of BRAINSWAY LTD/S during the second quarter worth $3,176,000. 10.84% of the stock is currently owned by hedge funds and other institutional investors.

BRAINSWAY LTD/S Company Profile

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.

Featured Article: Hold Rating

Get a free copy of the Zacks research report on BRAINSWAY LTD/S (BWAY)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for BRAINSWAY LTD/S (NASDAQ:BWAY)

Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit